Embolic strokes of undetermined source: Prevalence and patient features in the ESUS Global Registry

Abstract

Background

Recent evidence supports that most non-lacunar cryptogenic strokes are embolic. Accordingly, these strokes have been designated as embolic strokes of undetermined source (ESUS).

Aims

We undertook an international survey to characterize the frequency and clinical features of ESUS patients across global regions.

Methods

Consecutive patients hospitalized for ischemic stroke were retrospectively surveyed from 19 stroke research centers in 19 different countries to collect patients meeting criteria for ESUS.

Results

Of 2144 patients with recent ischemic stroke, 351 (16%, 95% CI 15% to 18%) met ESUS criteria, similar across global regions (range 16% to 21%), and an additional 308 (14%) patients had incomplete evaluation required for ESUS diagnosis. The mean age of ESUS patients (62 years; SD = 15) was significantly lower than the 1793 non-ESUS ischemic stroke patients (68 years, p ≤ 0.001). Excluding patients with atrial fibrillation (n = 590, mean age = 75 years), the mean age of the remaining 1203 non-ESUS ischemic stroke patients was 64 years (p = 0.02 vs. ESUS patients). Among ESUS patients, hypertension, diabetes, and prior stroke were present in 64%, 25%, and 17%, respectively. Median NIHSS score was 4 (interquartile range 2–8). At discharge, 90% of ESUS patients received antiplatelet therapy and 7% received anticoagulation.

Conclusions

This cross-sectional global sample of patients with recent ischemic stroke shows that one-sixth met criteria for ESUS, with additional ESUS patients likely among those with incomplete diagnostic investigation. ESUS patients were relatively young with mild strokes. Antiplatelet therapy was the standard antithrombotic therapy for secondary stroke prevention in all global regions.

Keywords

Stroke embolism cerebral embolism atrial fibrillation stroke—etiology diagnostic evaluation

Get full access to this article

View all access options for this article.

References

Hart

Diener

H-C

Coutts

et al.

Embolic strokes of undetermined source: The case for a new clinical construct. Lancet Neurol 2014; 13: 429–438.

Yiin

Geraghty

Schulz

et al.

Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: a population-based study. Lancet Neurol 2015; 14: 903–913.

Fisher

Adams

. Observations on brain embolism. J Neuropathol Exp Neurol 1951; 10: 92–94.

Fisher

. Concerning strokes. Canad Med Assoc J 1953; 69: 257–268.

Sacco

Ellenberg

Mohr

et al.

Infarcts of undetermined cause: The NINCDS Stroke Data Bank. Ann Neurol 1989; 25: 382–390.

NAVIGATE ESUS, https//clinicaltrials.gov/ct2/show/nct02313909 (accessed 1 July 2015).

Diener HC, Easton JD, Granger CB, et al. Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicyclic acid in patient with Embolic Stroke of Undetermined Source (RE-SPEcT ESUS). Int J Stroke 2015; 10: 1309–1312.

Ntaios

Papavasileiou

Milionis

et al.

Embolic strokes of undetermined source in the Athens Stroke Registry: a descriptive analysis. Stroke 2015; 46: 176–181.

Hart

. Cardiogenic embolism to the brain. Lancet 1992; 339: 589–594.

10.

Gladstone

Spring

Dorian

et al.

Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med 2014; 370: 2467–2477.

11.

Sanna

Diener

H-C

Passman

et al.

Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 2014; 370: 2478–2486.

12.

Arsava

Base

Atalar

Has

Oguz

Topcuoglu

. Ischemic stroke phenotype in patients with nonsustained atrial fibrillation. Stroke 2015; 46: 634–640.

13.

European Stroke Organization (ESO) Executive Committee and ESO Writing Committee. Guidelines for the management of ischemic stroke and transient ischemic attack 2008. Cerebrovas Dis 2008; 25: 457–505.

14.

Kernan

Ovbiagele

Black

et al.

Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack. A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2015; 45: 2160–2236.

15.

Lansberg

O'Donnell

Khatri

et al.

Antithrombotic and thrombolytic therapy for ischemic stroke: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e601S–e636S.

16.

ATTICUS, https//clinicaltrials.gov/ct2/show/nct02427126 (accessed 1 January 2016).